Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 8/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631608 | 0.84 | HSP90AA1 (0.72) | HSP90AA1NR3C2SMN1; SMN2KCNN4MAPK14 | |
| SCHEMBL1628953 | 0.84 | HSP90AA1 (0.72) | HSP90AA1NR3C2MAPK14PDE11AKDM5A | |
| SCHEMBL625870 | 0.81 | HSP90AA1 (0.68) | HSP90AA1NR3C2SMN1; SMN2KCNN4MAPK14 | |
| SCHEMBL1630437 | 0.81 | HSP90AA1 (0.67) | HSP90AA1NR3C2SMN1; SMN2MAPK14PDE10A | |
| SCHEMBL1629941 | 0.81 | HSP90AA1 (0.67) | HSP90AA1NR3C2SMN1; SMN2MAPK14PDE10A | |
| SCHEMBL1629661 | 0.79 | HSP90AA1 (0.65) | HSP90AA1NR3C2SMN1; SMN2MAPK14PDE10A | |
| SCHEMBL1629188 | 0.78 | HSP90AA1 (0.63) | HSP90AA1NR3C2SMN1; SMN2KCNN4MAPK14 | |
| SCHEMBL1630001 | 0.78 | HSP90AA1 (0.63) | HSP90AA1NR3C2SMN1; SMN2KCNN4MAPK14 | |
| SCHEMBL1629186 | 0.78 | HSP90AA1 (0.63) | HSP90AA1NR3C2SMN1; SMN2KCNN4MAPK14 | |
| SCHEMBL1629098 | 0.78 | HSP90AA1 (0.63) | HSP90AA1NR3C2SMN1; SMN2MAPK14PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | claimed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | claimed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NR3C2 558/4885SMN1; SMN2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.